Safety Study of Anti-IgE Immunotherapy in Allergic Patients
Safety Study of Anti-IgE Immunotherapy in Allergic Patients
The purpose of the study is to evaluate safety and efficacy of three doses and two dosing
 regimens of RP01 as an anti-IgE immunotherapy in allergic patients.
Immunotherapy is based on the principle of eliciting an immune reaction in order to block the
 negative effect of a specific disease-causing protein. The potential to treat diseases by
 means of immunotherapy instead of using conventional drugs represents an attractive
 opportunity in a number of chronic disease areas, including asthma and allergy. Resistentia's
 model to treat allergic diseases, and ultimately asthma, is to use the immune system to
 produce antibodies against the IgE molecules themselves. The resulting anti-IgE antibodies
 intercept and form complexes with the IgE molecules before they can bind to the mast cells
 and basophils and are thus able to block any allergen-triggered inflammatory reaction. The
 approach works in all types of IgE-mediated allergies independently of allergen, and also in
 patients sensitive to multiple allergens.

 Comparisons: Three doses and two dosing regimes of RP01 will be compared as regards safety
 and effect.
Inclusion Criteria:

 -  Allergy to at least one aero allergen

 -  Increased serum IgE level

 Exclusion Criteria:

 -  Diagnosis of asthma

 -  Recent use of systemic corticosteroids or immunosuppressive treatment

 -  Allergy vaccination therapy